What’s Working — and What’s Not — in Direct-to-Consumer Care

After a pandemic rush on telehealth and direct-to-consumer care, the dust is settling — and the market is saturated. Both new start-ups and legacy pharma companies started going direct to patients, with varying degrees of success. We’ll take a look at what aspects are stable, which are still trying to find footing, and make our predictions for long-term trends.